Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
Last trade$15.19
Day change-$0.135 (-0.88%)
Day range$15.11 – $15.56
Volume3,139,290
Market cap$10.38B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.38B
Price / earnings
30.79×
Price / book
1.78×
Price / sales
1.56×
EV / sales
2.05×
EV / EBITDA
14.96×
Profitability
Earnings per share
$0.50
Return on assets
2.9%
Return on equity
5.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.64×
Current ratio
1.89×
Quick ratio
1.27×
Cash ratio
0.34×
Cash flow
Price / cash flow
17.75×
Price / free cash flow
23.64×
Free cash flow
$439.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVTR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.7B
$1.69B
$1.58B
$1.66B
$1.62B
$1.68B
$1.58B
$1.69B
Cost of revenue
$1.16B
$1.16B
$1.08B
$1.14B
$1.1B
$1.13B
$1.05B
$1.12B
Gross profit
$534.8M
$537M
$500.7M
$523.9M
$526.5M
$554.1M
$534.9M
$562.9M
Selling, general and administrative
$395.3M
$415.2M
$401.2M
$392.4M
$390.3M
$425.3M
$387.5M
$371.4M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$395.3M
$415.2M
$401.2M
$392.4M
$1.18B
$425.3M
$387.5M
$371.4M
Operating income
$139.5M
$121.8M
$99.5M
$131.5M
-$648.8M
$128.8M
$147.4M
$191.5M
Interest expense
-$39.9M
-$39.4M
-$42.9M
-$40M
-$44.2M
-$43.4M
-$42.2M
-$44.9M
Income before taxes
$98M
$81.2M
$55.5M
$80.8M
-$689.5M
$81.7M
$85.7M
$584.2M
Income taxes
-$105.4M
$43.1M
$12.2M
$28.4M
$22.3M
$17M
$21.2M
$83.8M
Net income
$203.4M
$38.1M
$43.3M
$52.4M
-$711.8M
$64.7M
$64.5M
$500.4M
Net income attributable to common shareholders
$203.4M
$38.1M
$43.3M
$52.4M
-$711.8M
$64.7M
$64.5M
$500.4M
EBITDA
$244.8M
$227.4M
$204.5M
$234.8M
$240.7M
$231.5M
$247.1M
$292.4M
Basic earnings per share
$0.30
$0.06
$0.06
$0.08
-$1.04
$0.09
$0.09
$0.74
Diluted earnings per share
$0.30
$0.06
$0.06
$0.08
-$1.04
$0.09
$0.09
$0.74
Recent news
Company coverage with links to the original publishers.
Avantor, Inc. (AVTR) has earned a Zacks Momentum Style Score of A and a #2 (Buy) rating. The stock has outperformed its industry significantly, rising 5.3% weekly and 50.95% annually compared to the S&P 500's 13.12% yearly gain. Recent positive earnings estimate revisions for both current and next fiscal year support the bullish outlook.
Avantor, Inc. (AVTR) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is positioned in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals and positive earnings estimate revisions.
Avantor (AVTR) reported Q3 2026 earnings of $0.22 per share, beating consensus estimates of $0.21, with revenues of $1.7 billion exceeding expectations by 3.53%. The company has outperformed the market by 49.5% year-to-date. However, it received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 40% of Zacks industries.
Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations.
Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.